GRK4 Polymorphisms Blood Pressure Response to Candesartan

Essential Hypertension Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01629225
• Other study ID #: ThirdMMU
• Status: Recruiting
• Phase: Phase 4
• First received: June 24, 2012
• Last updated: November 17, 2014
• Start date: July 2013
• Est. completion date: July 2015

Study information

• Verified date: June 2013
• Source: Third Military Medical University
• Contact: Yu changqing, Doctor
• Phone: 02368731850
• Email: changqingyu-2[@]163.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.

Description:

All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥ 90 mmHg.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: July 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 30 Years to 75 Years

Eligibility

Inclusion Criteria:

• men and women with mild to moderate essential hypertension in southwestern Han Chinese

Exclusion Criteria:

• subjects unwilling to participate or subjects did not have all measurement required,

• subjects who were on medications, which affect blood pressure or

• whose DNA failed to amplify and 8 with errors in Mendelian segregation

Study Design

Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Essential Hypertension
• Hypertension

Intervention

Drug:
• Candesartan
To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension

Locations

Country	Name	City	State
China	Department of Cardiology, Daping Hospital, The Third Military Medical University	Chongqing

Sponsors (1)

Lead Sponsor	Collaborator
Third Military Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The subjects with GRK4 varirants may exert different response during 4 weeks of treatment with candesartan in patients with essential hypertension		two years	Yes